ArticleClinical kidney journal2026
Short versus long corticosteroid therapy for immune checkpoint inhibitors-induced acute tubulointerstitial nephritis.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune checkpoint inhibitor-associated interstitial nephritis: let's move forward addressing the unknowns.Clinical kidney journal · 2026Review
- Biopsy-Confirmed Acute Interstitial Nephritis in Patients Treated with Immune Checkpoint Inhibitors: A Single-Center Retrospective Case Series.Antibodies (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune-mediated acute tubulointerstitial nephritis (ICI-AIN) is the most common form of immune-mediated renal toxicity induced by immune checkpoint inhibitors (ICIs). It has an excellent response to corticosteroids, but there is no consensus on the most suitable steroid regimen. Methods: A multicentre retrospective study including 62 patients diagnosed with ICI-AIN treated with corticosteroids was conducted. Patients were categorized into two groups based on the duration of corticosteroid treatment: 'short course of steroids (SCS)' (<12 weeks) and 'long course of steroids (LCS)' (≥12 weeks). The study aims to compare the efficacy and toxicity of these two regimens. Results: Twenty-eight patients received SCS and 34 received LCS. Renal recovery was achieved in 89% of patients, with no differences between groups ( Conclusions: SCS is an effective and safe approach for the management of ICI-AIN. It offers a comparable rate of renal recovery, fewer adverse events and possibly more favourable oncological outcomes, compared with a prolonged regimen. Future prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.